A Call for Innovative Translational and Clinical Research to Address China's Unique Cancer Landscape.

The Chinese government has, in recent decades, implemented various administrative laws and regulatory policies to expedite cancer therapeutic development, boosting research and development pipelines for domestic pharmaceutical companies and clinical trials; however, China faces unique challenges given the high prevalence of certain cancer types and distinct disease burdens, some of which are frequently overlooked by international pharmaceutical companies. Given the substantial unmet need for China-specific cancer care, it is crucial to promote the development of innovative pharmaceutical and clinical research in China, with a particular emphasis on addressing tumors most prevalent in its population.

A bibliometric analysis of bladder cancer and microRNA research: Trends and advances from 2008 to 2022.

Bladder cancer (BC) is a significant global health issue with high incidence and mortality rates. MicroRNAs (miRNAs) play a crucial role in regulating gene expression and have been found to be dysregulated in BC. Understanding the role of miRNAs in BC development could lead to targeted therapies and improved patient management. Our study presents a thorough examination of the correlation between BC and miRNA research from 2008 to 2022. With the help of 3 powerful methods, including VOSviewer, Biblioshiny, and CiteSpace software, we analyzed the retrieved documents from "Core Collection databases online" on the Web of Science. In total, 798 articles were extracted from the Web of Science, and the number of published papers showed an upward trend from 2008 to 2019. The total number of citations was 21,233, of which the highest paper was a review article written by Chan Jiajia et al in 2018 with 752 citations. Based on the result of the coauthor analysis, Seki Naohiko was the most productive writer and China had the highest volume of published articles. Co-citation analysis was used to reveal the knowledge structure of the research field. In addition to the keywords "Bladder cancer" and "miRNA," "Proliferation," "Biomarkers," and "Apoptosis" were the high-frequency used keywords. Recently, increasingly researchers have paid more attention to the field about BC and miRNA around the worldwide. Through in-depth communication and close collaboration, the veil of miRNA in BC has gradually been unveiled. Bibliometric analysis helps to identify hotspots in research and areas for future investigation.

Electroacupuncture-modulated extracellular ATP levels in prefrontal cortex ameliorated depressive-like behavior of maternal separation rats.

Maternal separation (MS) is a type of early-life stress that has been linked to neuropsychiatric disorders, especially depression. Increasing evidence indicates that the adenosine triphosphate (ATP) level in the prefrontal cortex (PFC) is involved in the pathophysiology of depression. To investigate the potential relationship between ATP in PFC and antidepressant effects of electroacupuncture (EA) treatment, we assessed genes involved in ATP biosynthesis as well as the extracellular ATP levels in a rat model exposed to neonatal MS. Our results demonstrated that reduced expression of ABCG2 (an ATP-binding cassette protein) and ATP levels in the PFC of depressive-like rats exposed to MS can be attenuated by EA stimulus at the Baihui (GV20) and Yintang (GV29) acupoints. Moreover, the antidepressant effect of EA treatment was blocked by administration of suramin, a broad purinergic P2 receptor antagonist. Together, these results suggested that electroacupuncture may be able to modulate extracellular ATP levels in the PFC of depressive-like MS rats, potentially contributing to its antidepressant effects.

[Comparison of laparoscopic pyelolithotomy and percutaneous nephrolithotomy for renal pelvic stones larger than 2.5 cm].

OBJECTIVE: To compare the safety, efficacy and complications of laparoscopic pyelolithotomy (LPL) and percutaneous nephrolithotomy (PCNL) for treatment of renal pelvic stones larger than 2.5 cm. METHODS: From 2011 to 2016, 32 patients underwent LPL and another 32 patients received PCNL for renal pelvic stones larger than 2.5 cm. The baseline characteristics of the patients, stone size, mean operative time, estimated blood loss, postoperative hospital stay, stone-free rate, postoperative analgesia, blood transfusion, and the intraoperative, early postoperative and long-term complications were compared between the two groups. RESULTS: The baseline characteristics and stone size were comparable between the two groups. The mean operative time of LPL and PCNL was 117∓23.12 and 118.16∓25.45 min, respectively (P>0.05). The two groups showed significant differences in the mean estimated blood loss (63∓11.25 vs 122∓27.78 mL, P<0.01) and blood transfusion rate (0 vs 6.2%, P<0.01) but not in postoperative hospital stay (4.5∓1.34 vs 4.8∓2.2 days, P>0.05), stone-free rate (93.1% vs 87.5%, P>0.05) or the postoperative analgesia time (1.7∓0.5 and 1.9∓0.6 days, P>0.05). The incidence of intraoperative complications were significant lower in LPL group than in PCNL group (6.2% vs 25.0%, P<0.01), but the incidences of early postoperative complications (25.0% vs 34.4%, P>0.05) and long-term postoperative complications (9.4% vs 12.5%, P>0.05) were similar between them. CONCLUSION: PCNL is the standard treatment for pelvic stones larger than 2.5 cm, but for urologists experienced with laparoscopic technique, LPL provides a feasible and safe option for management of such cases.